4-chloro-N-(4-methoxyphenyl)phthalazin-1-amine | 677323-02-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-chloro-N-(4-methoxyphenyl)phthalazin-1-amine
• CAS: 677323-02-3
• 化学式: C₁₅H₁₂ClN₃O
• 分子量: 285.733
• InChiKey: GWPLXCCQMZGMBV-UHFFFAOYSA-N

物化性质

• 沸点：
  504.4±45.0 °C(Predicted)
• 密度：
  1.347±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  47
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-chloro-N-(4-methoxyphenyl)phthalazin-1-amine 、 4-氨基甲酰苯硼酸 在 bis-triphenylphosphine-palladium(II) chloride 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 4-{4-[(4-Methoxyphenyl)amino]phthalazin-1-yl}benzamide
  参考文献：
  名称：

  Arylphthalazines: Identification of a new phthalazine chemotype as inhibitors of VEGFR kinase

  摘要：

  A novel class of 4-arylamino-phthalazin-1-yl-benzamides is described as inhibitors of vascular endothelial growth factor receptor II (VEGFR-2). Several compounds display potent VEGFR-2 inhibitory activity with an IC50 as low as 0.078 mu M in an HTRF enzymatic assay. These compounds are relatively selective against a small kinase panel. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.07.064
• 作为产物：
  描述：

  苯酐 在 hydrazine hydrate 作用下， 以 乙醇 为溶剂， 反应 9.0h， 生成 4-chloro-N-(4-methoxyphenyl)phthalazin-1-amine
  参考文献：
  名称：

  酞嗪作为新型非激酶 TGFβ 通路抑制剂的发现和生物学评价

  摘要：

  TGFβ对于上皮和神经组织的稳态、伤口修复和调节免疫反应至关重要。其失调与大量疾病有关，其中改变肿瘤微环境是重要的临床意义之一。尽管进行了各种尝试，但仍然没有 FDA 批准的抑制 TGFβ 途径的疗法。主要的主流方法包括通过以下方式损伤 TGFβ通路抑制TGFβRI激酶。为了识别基于非受体激酶的抑制剂以损害 TGFβ 信号传导，通过计算研究丰富了内部化学库，以消除 TGFβRI 激酶活性。针对在 TGFβ-Smad 依赖性转录控制下用萤火虫荧光素酶基因改造的细胞系筛选选定的化合物。结果表明具有酞嗪核心的分子对 TGFβ-Smad 信号传导具有中等效力。合成了一系列酞嗪化合物并评估其效力。最有希望的化合物 ( 10p ) 的 IC 50为 0.11 ± 0.02 μM，经证实在高达 12 μM 时无细胞毒性，选择性指数约为 112 倍。同时，10p证实使用蛋白质印迹可减少 Smad 磷酸化，而不显示对

  DOI：

  10.1016/j.ejmech.2021.113660

文献信息

• PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF
  申请人：Cai Sui Xiong

  公开号：US20080020985A1

  公开（公告）日：2008-01-24

  Disclosed are 1-arylamino-phthalazines, 4-arylamino-benzo[d][1,2,3]triazines, and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.

  本发明披露了1-芳基氨基-菲啶嗪、4-芳基氨基苯并[d][1,2,3]三嗪及其类似物，它们有效激活半胱氨酸蛋白酶和诱导细胞凋亡。本发明的化合物在治疗各种临床病症中具有用途，这些病症中存在不受控制的异常细胞生长和扩散。
• Synthesis and biological activity of aminophthalazines and aminopyridazines as novel inhibitors of PGE2 production in cells
  作者：Federico Medda、Earlphia Sells、Hui-Hua Chang、Justin Dietrich、Shashi Chappeta、Breland Smith、Vijay Gokhale、Emmanuelle J. Meuillet、Christopher Hulme

  DOI：10.1016/j.bmcl.2012.11.030

  日期：2013.1

  This Letter reports the synthesis and biological evaluation of a collection of aminophthalazines as a novel class of compounds capable of reducing production of PGE(2) in HCA-7 human adenocarcinoma cells. A total of 28 analogs were synthesized, assayed for PGE2 reduction, and selected active compounds were evaluated for inhibitory activity against COX-2 in a cell free assay. Compound 2xxiv (R-1 = H, R-2 = p-CH3O) exhibited the most potent activity in cells (EC50 = 0.02 mu M) and minimal inhibition of COX-2 activity (3% at 5 mu M). Furthermore, the anti-tumor activity of analog 2vii was analyzed in xenograft mouse models exhibiting good anti-cancer activity. (C) 2012 Elsevier Ltd. All rights reserved.
• Design and synthesis of 3-aminophthalazine derivatives and structural analogues as PDE5 inhibitors: anti-allodynic effect against neuropathic pain in a mouse model
  作者：Maud Bollenbach、Claire Lugnier、Mélanie Kremer、Eric Salvat、Salim Megat、Frédéric Bihel、Jean-Jacques Bourguignon、Michel Barrot、Martine Schmitt

  DOI：10.1016/j.ejmech.2019.05.026

  日期：2019.9

  Neuropathic pain is a chronic pain caused by a lesion or disease affecting the somatosensory nervous system. To date, no specific treatment has been developed to cure this pain. Antidepressants and anticonvulsant drugs are used, but they do not demonstrate universal efficacy, and they often cause detrimental adverse effects. Some studies highlighted the efficacy of sildenafil, a well-known inhibitor of phosphodiesterase 5 (PDE5, (IC50=3.3 nM)), in models of pain. Based on these results, we focused our attention on MY 5445, another known PDE5 inhibitor. Homologues, isosteres and structural analogues of MY 5445 were designed and all synthesized compounds were evaluated for their inhibitory activity toward PDE5. Selectivity profiles towards other PDE1-4 isoenzymes, water solubility and stability in acidic medium of the most potent PDE5 inhibitors were determined and the aminophthalazine 16h and its mimetic 41n (3-aminoindazole) were evaluated in comparison to MY 5445 (4b) in vivo in a model of neuropathic pain induced by sciatic nerve cuffing in mice (3 and 0.5 mg/kg, ip twice a day). Both compounds showed the same efficacy on neuropathic allodynia as MY 5445, and thus produced a significant relief of mechanical hypersensitivity after 12 days of treatment. (C) 2019 Elsevier Masson SAS. All rights reserved.
• EP1833803A4
  申请人：——

  公开号：EP1833803A4

  公开（公告）日：2009-08-05
• US7842805B2
  申请人：——

  公开号：US7842805B2

  公开（公告）日：2010-11-30